Claims
- 1. A heterocyclic compounnd of the formula ##STR106## wherein Het represents imidazolyl, either unsubstituted or substituted by halogen, hydroxyl, lower alkyl, lower alkoxy, hydroxymethyl, phenyl, benzyl, cyano, amino, aminoalkyl, amidinoalkyl; Z represents sulfur or oxygen; X represents the formula N--R.sub.1 wherein R.sub.1 represents cyano, unsubstituted or lower alkyl-substituted carbamoyl, unsubstituted or lower-alkyl-substituted thiocarbamoyl; Y represents alkyl substituted by hydroxyl, amino or halogen, cycloalkyl of 3-6 carbon atoms, lower alkenyl, lower alkynyl, aryl, unsubstituted or substituted by hydroxyl, amino or halogen, aralkyl, unsubstituted or substituted by hydroxyl, amino, or halogen, cyano, or carbamoyl; and m and n represent an integer of 1 to 3; or a pharmacologically acceptable acid addition salt thereof.
- 2. A compound according to claim 1, which is N-2-propynyl-3-[(5-methylimidazol-4-yl)methylthio]-propionamidine and the dihydrochloride salt thereof.
- 3. A compound according to claim 1, which is N-carbamoyl-3-(4-methyl-5-imidazolylmethylthio)-propionamidine.
- 4. A composition for inhibiting gastric acid secretion containing as the active ingredient an effective amount of a heterocyclic compound of claim 1 and a pharmaceutically acceptable carrier.
- 5. The composition according to claim 4, wherein the active ingredient is N-2-propynyl-3-[(5-methylimidazol-4-yl)methylthio]-propionamidine or the dihydrochloride salt thereof.
- 6. The composition according to claim 4, wherein the active ingredient is N-carbamoyl-3-(4-methyl-5-imidazolyl-methylthio)-propionamidine.
- 7. A composition for oral administration as claimed in claim 4, containing a sufficient amount of said compound to provide a dose of from 0.4 to 1 g per day when administered in 1 to 4 divided doses per day.
- 8. A method of inhibiting gastric acid secretion in a warm blooded animal which comprises administering an effective amount of the composition of claim 4 to said warm blooded animal.
- 9. The method as claimed in claim 8 wherein said composition is administered orally in an amount varying from 0.4 to 1 g each day.
Priority Claims (2)
Number |
Date |
Country |
Kind |
52-104079 |
Aug 1977 |
JPX |
|
53-86944 |
Jul 1978 |
JPX |
|
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of copending U.S. application Ser. No. 934,276, filed Aug. 16, 1978, now U.S. Pat. No. 4,252,819.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3558640 |
Shen et al. |
Jan 1971 |
|
4104382 |
Black et al. |
Aug 1978 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
1398426 |
Jun 1975 |
GBX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
934276 |
Aug 1978 |
|